
On CNBC's “Halftime Report Final Trades” on Tuesday, Jason Snipe, founder and chief investment officer of Odyssey Capital Advisors, said he is staying long on AbbVie Inc. (NYSE:ABBV).
Supporting his view, Guggenheim analyst Vamil Divan maintained an AbbVie Buy rating on Oct. 20, raising the price target from $227 to $242.